SCHEMBL2833338

SCHEMBL2833338

Cc1cc(C(=O)C(NC(=O)OC(C)(C)C)c2ccc(Cl)c(Cl)c2)ccc1-c1cncc(F)c1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 7/20 0.42
MDM2 Q00987 3/20 0.39
ROCK2 O75116 2/20 0.38
ROCK1 Q13464 2/20 0.38
EIF2S1 P05198 1/20 0.38
EIF2AK3 Q9NZJ5 1/20 0.38
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35
S1PR1 P21453 4/20 0.35
AAK1 Q2M2I8 2/20 0.35
KLRK1 P26718 1/20 0.34
MICA Q29983 1/20 0.34
RAET1L Q5VY80 1/20 0.34
TRPA1 O75762 1/20 0.34
CTSA P10619 1/20 0.34
S1PR4 O95977 2/20 0.34
ABL1 P00519 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2836835 0.90 S1PR3 (0.41) S1PR3MDM2ROCK2ROCK1AKR1C3
SCHEMBL2837542 0.85 S1PR3 (0.43) S1PR3MDM2S1PR1AAK1KLRK1
SCHEMBL2834200 0.83 EIF2S1 (0.38) S1PR3ROCK2ROCK1EIF2S1EIF2AK3
SCHEMBL2838232 0.81 S1PR3 (0.46) S1PR3MDM2ROCK2AAK1KLRK1
SCHEMBL2839096 0.79 S1PR3 (0.42) S1PR3ROCK2ROCK1AKR1C3AKR1C2
SCHEMBL2843147 0.75 AKR1C3 (0.41) S1PR3ROCK2ROCK1AKR1C3AKR1C2
SCHEMBL2835001 0.75 S1PR3 (0.48) S1PR3MDM2S1PR1TRPA1S1PR4
SCHEMBL2834950 0.75 S1PR3 (0.40) S1PR3AAK1KLRK1MICARAET1L
SCHEMBL2835057 0.74 S1PR3 (0.48) S1PR3MDM2S1PR1TRPA1S1PR4
SCHEMBL2836642 0.74 S1PR3 (0.48) S1PR3MDM2S1PR1TRPA1S1PR4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8367838-B2 Amines or amino alcohols as GLYT1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2013-02-05 US disclosed
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS KOLCZEWSKI SABINE (DE) 2012-09-13 US disclosed
EP-2398558-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. Hoffmann-La Roche AG (CH) 2011-12-28 EP disclosed
WO-2010094659-A1 AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-08-26 WO disclosed
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS HOFFMANN-LA ROCHE, INC. 2010-08-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232033-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885MDM2 4155/4885ROCK2 2900/4885
US-20100210592-A1 AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS GFPT1, CEPT1, SLC18A2 S1PR3 2311/4885MDM2 4155/4885ROCK2 2900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.